According to a regulatory filing with the SEC, Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) has recently entered into Settlement and License Agreements with Apotex Inc. and Apotex Corp. regarding ongoing patent litigation. These agreements were made to settle the dispute related to Apotex's generic version of the Company's Oxtellar XR.

The filing states that Apotex's Abbreviated New Drug Application (ANDA) included a paragraph IV certification seeking approval to market the generic product before the expiration of certain United States Patents-in-Suit.

Under the terms of the agreements, all claims, counter-claims, and defenses asserted in the litigation will be dismissed. Apotex has been granted a license to market the generic version of Oxtellar XR in the United States starting from September 1, 2024, or earlier under certain circumstances. Supernus Pharmaceuticals retains the right to market an authorized generic product.

Oxtellar XR is a prescribed medication specifically designed to address partial-onset seizures in individuals aged six and above, utilizing extended-release tablets containing oxcarbazepine.

On Friday, $SUPN closed at $32.63, down $0.90 (2.68%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)